More importantly, we show that targeting FAM111B with either adeno-associated virus (AAV) or sGLNP containing siFAM111B inhibits HCC progression in vivo, indicating a new therapeutic strategy for treating HCC. Here, FAM111B is linked to hepatocellular carcinoma.